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AT cell antigen receptor (TCR) transmembrane sequence derived peptide (CP) has been shown to inhibit T cell activation both in vitro and in
vivo at the membrane level of the receptor signal transduction. To examine the effect of sugar or lipid conjugations on CP function, we linked CP
to 1-aminoglucosesuccinate (GS), N-myristate (MYR), mono-di-tripalmitate (LP1, LP2, or LP3), and a lipoamino acid (LA) and examined the
effects of these compounds on T cell activation in vitro and by using a rat model of adjuvant-induced arthritis, in vivo. In vitro, antigen
presentation results demonstrated that lipid conjugation enhanced CP's ability to lower IL-2 production from 56.99%±15.69 S.D. observed with
CP, to 12.08%±3.34 S.D. observed with LA. The sugar conjugate GS resulted in only a mild loss of in vitro activity compared to CP (82.95%±
14.96 S.D.). In vivo, lipid conjugation retarded the progression of adjuvant-induced arthritis by approximately 50%, whereas the sugar conjugated
CP, GS, almost completely inhibited the progression of arthritis. This study demonstrates that hydrophobic peptide activity is markedly enhanced
in vitro and in vivo by conjugation to lipids or sugars. This may have practical applications in drug delivery and bioavailability of hydrophobic
peptides.
© 2006 Elsevier B.V. All rights reserved.Keywords: Peptides; Lipopeptides; Peptide conjugation; Transmembranes; T cell antigen receptor1. Introduction
The diagnosis and treatment of clinical diseases with peptides
are quickly becoming a reality with many peptides already being
applied in the clinical setting. Two diagnostic kits presently
available employing peptides as their major effector are
technetium Tc99m-apcitide for acute deep vein thrombosis,
which binds with high specificity and affinity to activated
platelets [1], and indium In-111 pentetreotide (OctreoScan®) [2]
which is capable of scintographic localization of primary and
metastatic neuroendocrine tumors bearing somatostatin receptors.
To date, relatively few peptide drugs are available commercially,
with one of the most recently approved by the US Food and Drug⁎ Corresponding author. Tel.: +61 2 9845 8099; fax: +61 2 9845 8317.
E-mail address: nickm@westgate.wh.usyd.edu.au (N. Manolios).
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.04.013Administration being the eagerly anticipated HIV fusion inhibitor
peptide, enfuvirtide (Fuzeon®, formerly T-20). This peptide has
been designed to bind to a structural intermediate of gp41's fusion
process, thereby inhibitingHIV-1 fusion and subsequent infection
of CD4+ T cells [3]. A 25-amino-acid peptide isolated from the
Cone Snail (ConusMagus), termedω-conotoxin (ziconotide), has
recently entered the market as a non-addictive treatment for pain
relief in cancer and HIV patients.ω-Conotoxin acts by selectively
inhibiting calcium channels [4] and has been shown to be 1000
times more active than morphine in animal models [5]. Another
peptide on the market is glatiramer acetate (Copaxone, copoly-
mer-1), which has been approved in the treatment for multiple
sclerosis. Glatiramer acetate is a peptide mimic of myelin basic
protein which consists of fixed ratios of alanine, lysine, glutamic
acid, and tyrosine and is likely to inhibit multiple sclerosis by
switching the immune response from the pro-inflammatory Th1
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available peptides, such as the spleen peptide preparation Poly-
erga [7], Prograf (tacrolimus or FK506) [8], or Thymosin-α [9]
are also aimed at various forms of immunoregulation.Many other
peptides are in various phases of clinical trial and are expected to
be on the market in the near future against various cancers [10]
such as the 11-amino-acid peptide P-108 against breast cancer
[11], with many more being developed [12].
A number of difficulties must be overcome prior to the wid-
espread clinical usage of peptides. These include peptide solub-
ility, mode of administration, and the subsequent delivery of the
peptide in its active form (reviewed by Ali andManolios [13]). In
most cases, peptides translocate across the cell membrane either
by a receptor-mediated energy-dependent process or by passive
diffusion [14]. In the latter case, this is generally facilitated by
increasing the lipophilicity of peptides [15]. Lipid conjugation
can be performed with various lipids employing many different
strategies. For example, Schelhaas et al. [16] have utilized enzy-
me-labile protecting groups and a metal sensitive allyl ester to
successfully lipidate peptides corresponding to the C terminus of
the N-Ras protein. A discussion on the development of various
protecting group techniques used in peptide lipidation is furthered
in a review by Peters et al. [17]. Mora and Tam [18] describe a
conjugation technique employing branched lysines and a tripa-
lmitoyl S-glycerine cysteine to create a lipidated multiple antigen
peptide.A reversible lipidization technique, as described byWang
et al., has resulted in an anti-diuretic peptide's activity being in-
creased 250-fold in a rat model [19]. Tris-linkers have also been
used to conjugate 1, 2, or 3 lipid groups to peptideswhile avoiding
structural isomerization [20]. Lipoamino acids, as used by Toth et
al. [21], are also being synthesized to increase the membrane
permeability of various peptides.
The therapeutic success of peptides combined with advances in
biotechnology is hailing a paradigm shift in peptide applicaion,
drug design, anddiscovery.Whereas drugswere once derived from
the purification of natural compounds, it is now possible to design
and synthesize new compounds based on structure–function
relationships. Otvos et al. [22] have designed a potent anti-micro-
bial peptide statistically based on native proline-rich sequences
from known antibacterial peptides followed by an optimisation
step involving the replacement of non-productive residues. Ano-
ther example is the neuraminic acid derivative, zanamivir (Re-
lenza). Using 3D crystallography, it was possible to design a new
drug able to sterically inhibit the active site of the influenza
neuraminidase binding site leading to potent anti-influenza activity
[23].Hence, drugsmay be able to be designed based on their ability
to disrupt the tertiary structure of proteins, either by the competi-
tive/steric inhibition of active sites or by the inhibition of receptor
activation as is the case with the T cell receptor mimic peptide
termed core peptide (CP) [24].
The TCR is composed of at least seven transmembrane
proteins that are responsible for recognizing antigens presented
in the context of MHC-encoded proteins on the surface of
antigen-presenting cells. The TCR α/β chains are responsible
for antigen recognition, while the invariant CD3 chains (γ, δ, ε,
and ζ) are responsible for transmitting antigen recognition
signals from the TCRα/β subunit through to the cytoplasm,resulting in T cell activation and an immune response [25]. An
important aspect of TCR structure and assembly is the presence
of at least one charged amino acid within each subunits trans-
membrane domain [26]. The invariant CD3 chains each have
one negative charge within their transmembrane domains,
whereas the TCR subunits have positive charges, with the
TCRα possessing two, and the TCRβ with one. These trans-
membrane charges have been shown to be an essential requ-
irement for proper TCR assembly. Call et al. have recently
proposed the TCR is composed of four separate dimers, the
TCRαβ antigen recognition subunit, and the CD3δε, CD3γε,
and CD3ζζ signalling molecules [26]. In this model, the basic
transmembrane lysine residue of the TCRα interacts with the
two acidic aspartate residues of the CD3δε, and the TCRα's
basic arginine residue interacts with the 2 acidic aspartate
residues of the CD3ζζ dimer. The TCRβ's single basic residue
(lysine) was shown to interact with the acidic glutamate and
aspartate residues of the CD3γε dimer [26]. This results in a
TCR structure consisting of three separate trimers character-
ized by the interactions between one basic and 2 acidic residues
to produce TCRα-CD3δε, TCRα-CD3ζζ, and TCRβ-CD3γε
trimers [26].
CP was synthesized as a direct copy of the nine amino acid
sequence within the TCR-α transmembrane region (G–L–R–I–
L–L–L–K–V), containing the two basic residues, arginine and
lysine. This peptide was subsequently shown to inhibit T-cell-
mediated responses both in vitro and in vivo by inhibiting IL-2
production in T cells following antigen recognition and by con-
ferring therapeutic protection in rats with adjuvant-induced art-
hritis [24]. Based on current evidence, CP acts at the cell surface
membrane level to disrupt TCR signal transduction between the
antigen recognizing TCR-α/β and the signal transduction chains
of the CD3 subunits [27,28] by a non-receptor-mediated process.
Surface plasmon resonance (SPR) has been used to determine
CP's affinity for membranes [29] and shown to bind irreversibly
to model membrane bilayers composed of either dimyristoyl-
phosphatidylcholine or dimyristoyl-phosphatidylglycerol.
CP is poorly soluble when tested in vitro requiring solu-
bilisation in DMSO or acetic acid. Heating, shaking, soni-
cation, and repeated lyophilization improve solubility, but
solubility remains poor. To overcome some of these difficul-
ties, Gollner et al. [30] emulsified CP in a cream and applied it
to skin with effective results. In this paper, Gollner et al.
showed that topical application of CPwas able to locally inhibit
the elicitation of contact sensitivity in mice when applied as
either a cream or when DNA encoding CP was injected into the
skin. Similarly, in an ingenious means of drug deliveryMahnke
et al. have demonstrated that transduction of dendritic cells by
retroviral agents containing CP constructs were able to secrete
CP in a localized and antigen-specific manner capable of in-
hibiting experimental allergic encephalomyelitis in a rodent
model [31]. Although these papers showed the clinical rele-
vance and potential of CP, a more practical and readily avail-
able delivery method still needs to be developed.
This study examines the influence of lipid and/or sugar con-
jugations on hydrophobic peptide (CP) function and correlates
this with the analogues behaviour in model membranes using
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adjuvant arthritis model was examined.
2. Materials and methods
2.1. Cells used
The following cell lines were used. 2B4.11, a murine T cell hybridoma that
expresses a complete antigen receptor on the cell surface and produces IL-2
following antigen recognition (cytochrome c). CTLL cells, an IL-2-dependant T
cell line, for conventional biological IL-2 assays. The B cell hybridoma line
LK35.2 (LK, I-Ek bearing), which acts as the antigen-presenting cell. The
hybridomas were grown in T cell medium (RPMI 1640 medium containing 10%
fetal calf serum (FCS), glutamine (2 mM), beta-mercaptoethanol (0.002%),
penicillin/streptomycin (50 U/ml).
2.2. Antibodies
145-2C11, a hamster anti-mouse-CD3ε antibody [32], was purified from
supernatant in laboratory. H57-597, an antibody directed against the TCR Cβ
FG loop of the TCR-β chain [33,34] (Becton Dickinson Pharmingen Catalogue
#553167 for plate-bound stimulation and Santa Cruz Catalogue #sc-18904 l for
soluble antibody stimulation).
2.3. Peptides/lipopeptide synthesis
Fig. 1 shows the structure of each peptide conjugate. Peptideswere synthesized by
manual solid phase peptide synthesis, using side-chain protected Fmoc-conjugated
amino acids. Peptideswere thenpurified usingVydacC18 reverse-phase columnonan
Agilant 1100 series HPLC and analysed by mass spectroscopy. Lipopeptides were
synthesized using the Tris-linked technology as previously described by Whittaker
et al. [20]. Briefly, the C-terminal valine of protected CP was linked to Gly-Tris–
palmitate, –dipalmitate and –tripalmitate, followed by purification using a silica
column and organic eluants (chloroform and methanol) and the products analysed byFig. 1. Structure of synthesized conjugates.mass spectroscopy (MS). The synthesis of the LA and GS was accomplished auto-
matically by a stepwise solid-phase procedure on a MBHA Novabiochem resin
(substitution 0.48mmol/g resin) and their primary structure verified byMS andNMR.
The lipoamino acid synthesis and the 1-amino-glucosesuccinate synthesis were coup-
led to the resin peptides manually. The synthesis of these compounds has previously
been described [35,36]. Briefly, peptide construction was achieved using a 4-fold
excess of preformed symmetrical anhydride of N-Boc amino acids in dichlorome-
thane/N-methylpyrrolidone. The protecting groups were Boc groups for the α-amino-
termini. For all residues, the first coupling was done with the preformed symmetrical
anhydride in dichloromethane, a second coupling in dichloromethane/N-methylpyr-
rolidone. After the second coupling, deprotection of the N-termini was performed in
65% TFA in dichloromethane (20 ml for 1 min, then another 20 ml for 10 min). The
deprotected resin peptide was neutralised with 10% di-isopropylethylamine in
dichloromethane. The peptide was removed from the resin support with the high HF
method (1.5 ml cresol, 1.5 ml thiocresol, 20 ml HF) to yield the crude peptide, which
was precipitated with ethyl acetate and redissolved in 6M guanidine HCl–0.1M Tris
solution (20 ml).
Peptide purification was done on a Vydac C18 5 RAC column. HPLC grade
acetonitrile (Aldrich) and water were filtered through a membrane filter and
degassed with helium prior to use. All HPLC solvents contained 0.1% trifluo-
roacetic acid. Analytical separation was achieved with a solvent gradient begin-
ning with 0% acetonitrile, increasing constantly to 60% acetonitrile at 30 min,
staying at this concentration for 20 min and decreasing steadily to 0% acetonitrile
for 10 min at a constant flow of 0.7 ml/min. For preparative separation, a TSK-
GEL preparative C18 column was used. Separation was achieved with a solvent
gradient beginning with 0% acetonitrile, increasing constantly to 60% ace-
tonitrile at 180 min, staying at this concentration for 60 min and decreasing
steadily to 0% acetonitrile for 30 min at a constant flow of 7 ml/min. The gradient
was controlled by two microprocessor-controlled Gilson 302 single piston
pumps. Compounds were detected with a Holochrome UV–VIS detector at
214 nm (analytical) and 230 nm (preparative). Chromatographs were recorded
with an LKB 2210 single channel chart recorder.
Since the 2-aminododecanoic acid was used as a racemate, the synthesized
LA was a diastereomeric mixture.
Myristoylated-CP (MYR) was purchased from Auspep (Melbourne Australia)
with a purity greater than 90%. CP and its lipid conjugates were dissolved in 100%
DMSO to stock concentrations of 10mM, 5mM, and 2mMandwere diluted inmedia
to final concentrations of 50 μM, 25 μM, and 10 μM in 0.5% DMSO for each
experiment. As such, each lipid conjugate was compared to a 0.5% DMSO control.
Stock GS was dissolved in distilled water to stock concentrations of 1 mM, 0.5 mM,
0.2 mM, and 0.1 mM and were diluted in media to a final concentration of 50 μM,
25 μM, 10 μM, and 5 μM. GS results are expressed relative to diluent control.
2.4. Antigen presentation assay
To establish the ability of CP conjugates to inhibit Tcell activation the antigen
presentation model was used. In this system, cytochrome c-specific mouse
hybridoma T cells were incubated with antigen-presenting cells, cytochrome c,
and the conjugate of interest. The amount of IL-2 produced during this overnight
stimulation was quantitated using the IL-2-dependant CTLL-2 cell line. This has
been previously described by Manolios et al. [37]. Briefly, mouse T cell
2B4.11 hybridoma (5×104) were cultured in microtiter wells with LK35.2
antigen-presenting B cells (5×104) and 50 μM pigeon cytochrome c. After 20 h,
100 μl of assay supernatant was removed and assayed for the presence of IL-2 in
serial 2-fold dilutions. CTLL cells (1–2×104) were then cultured in the super-
natant for 20 h, pulsed with 0.5 μCi [3H] thymidine for 5 h and harvested on glass
fibre filters (Packard Biosciences catalogue number 6005412) using a cell
harvester (TiterTek). A Packard Biosciences Top Count NXT microplate scinti-
llation and luminescence counter was used to measure [3H] thymidine uptake.
Peptide conjugates were all tested at 50 μM, 25 μM, and 10 μM in triplicate per
assay. Each assay was performed at least three times.
2.5. Viability and proliferation assay
2B4.11 T cells (1×105) were cultured in microtiter wells in the presence of the
peptide conjugates at 50 μM. After 20 h, 30 μl was removed and cells assessed for
viability by trypan blue staining. The remaining culture was then pulsed with 0.5 μCi
[3H] thymidine for 5 h, harvested, and quantitated for [3H] thymidine uptake.
Fig. 2. The influence of CP conjugates on IL-2 production induced by antigen
activation. Antigen presentation assay results showing the %IL-2 produced, as
compared to 0.5% DMSO control, in the presence of CP, LA, MYR,
lipopeptides (LP1, LP2, LP3) and GS. GS is calculated relative to a diluent
control set to 100% (control not shown). Conjugates were tested in triplicate per
experiment, and each experiment was performed on at least three separate
occasions. All samples presented at 50 μM.
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96-well flat bottom microplate (Becton Dickinson, Australia) were coated
with 10 μg/ml of 145-2C11 (laboratory purified) or H57-597 (Becton Dickinson
Pharmingen Catalogue #553167) in 0.1%BSA/PBS overnight at 4 °C. Plates
were then washed with media prior to the addition of 1×105 2B4.11 cells in the
presence of each peptide conjugate (at 50 μM and 0.5% DMSO) in 250 μl. Each
reaction was performed in triplicate. Experiments were then continued as per the
antigen presentation experiment described above.
2.7. CD3 and TCRα/β cross-linking (soluble antibody)
T cell hybridoma, 2B4.11 cells (1×105) were cultured in 96-well, round
bottom plates in the presence of LK cells (5×104), 0.5 μg/ml of soluble 145-2C11
(laboratory purified) or H57-597 (Santa Cruz Catalogue #sc-18904L), and each
peptide conjugate (50 μM and 0.5% DMSO) to a final volume of 250 μl. Plates
were incubated for 24 h at 37 °C with 5% CO2. Supernatants were then collected
and analysed for IL-2 content. All conjugates were tested simultaneously in
triplicate wells, and each experiment was performed on three separate occasions.
2.8. PMA and ionomycin stimulation
PMA (40 ng/ml) and ionomycin (5 μg/ml) were added to 2B4 cells (5×104)
and incubated with each CP-conjugate at 50 μM in 0.5% DMSO in 96-well,
round bottommicrotiter plates for 24 h at 37 °C with 5%CO2 in a total volume of
250 μl. Supernatants were then collected and analysed for IL-2 production. All
CP conjugates were tested simultaneously in triplicate wells, and each expe-
riment was performed on three separate occasions.
2.9. Staphylococcal enterotoxin A activation
T cell hybridoma, 2B4.11 (5×104), were incubated with LK 35.2 cells
(5×104) in the presence of 100 ng/ml of Staphylococcal enterotoxin A and
50 μM of each peptide overnight at 37 °C/5% CO2 in round bottomed 96-well
plates. T cell stimulation was assessed by quantifying IL-2 production as des-
cribed above.
2.10. Preparation of small unilamellar vesicles (SUV)
Dimyristoyl phosphatidyl choline (DMPC) and dimyristoyl phosphatidyl
glycerol (DMPG)were dissolved in dry chloroform and chloroform/methanol (2:1)
respectively to give 10mg/ml solutions. These solutionsweremixed in appropriate
proportions and subsequently evaporated under reduced pressure. The resulting
lipid filmwas dried overnight in vacuo. Lipidswere then hydrated by resuspending
in HEPES buffer for 60 min at 34 °C to give a 0.5 M concentration in respect of
phospholipids. The solution was then sonicated in an ultrasonic bath for 20 min.
Eight cycles of freeze/thawing was followed by extrusion through polycarbonate
filters, first 100 nm (21 times), and then 50 nm (21 times) pore diameter, using a
Lipo-fast apparatus (Avestin, Ottawa, Canada). The resulting SUVs were used
immediately. DMPC and DMPG were used in 70:30 ratio (DMPC:DMPG) to
approximate the proportion found in vertebrate cell membranes.
2.11. Binding analysis by surface plasmon resonance (SPR)
SPR was carried out on a BIAcore 2000 instrument using Pioneer Sensor Chip
L1 and HEPES (HBS-N, Biacore, Upssala, Sweden) as running buffer. The chip
surface was cleaned with 40 mM octyl glycoside (30 μl, 10 μl/min) followed by
running buffer (100 μl, 10 μl/min). Liposomes (SUV) were injected (100 μl, 5 μl/
min) giving approximately 8000 response units (RU). 10 mMNaOH (40 μl, 10 μl/
min) removed any multilamellar vesicles from the surface, which was followed by
10 mM glycine pH 2.2 (10 μl, 10 μl/min) before injecting the peptide of interest
(100 μl, 5 μl/min). After peptide injection, the dissociation stage was 1200 s.
Regeneration of the sensor chip was achieved with 40 mM β-octyl glycoside
(30 μl, 10 μl/min). All SPR experiments were run at 25 °C, and all analyses were
performed using the BIAevaluation software (Biacore, Upssala, Sweden). All
peptides were prepared at 50 μM and 0.5% DMSO in HEPES.2.12. Adjuvant-induced arthritis model
FemaleWistar rats, aged 8–10weeks, were injected subcutaneously at the base
of the tail with 1mgof heat-killedMycobacterium tuberculosis suspended in 100μl
of squalene. One day after the first signs of arthritis appeared (usually around 10 to
12 days later), rats were subcutaneously treated for 4 consecutive dayswith 6mg of
peptide suspended in squalene (CP, n=5; LA, n=5; LP3, n=5; MYR, n=4), or
dH2O (GS, n=3), or 1.25mg cyclosporin (n=5) in dH2O (5mg/kg). Controls were
injected with squalene alone (n=5). Arthritis severity was scored daily using 5
parameters: rat weight, number of arthritic joints, and by using digital calipers, paw
thickness, paw width, ankle width were measured. All procedures were performed
under general anaesthesia with isofluorane, and analgesics (buprenorphine) were
given to relieve pain. Paw thickness, paw width, and ankle width, measurements
were then combined and averaged for each group to give an overall assessment of
the severity of arthritis for each peptide conjugate tested.
3. Results
3.1. Effect of CP conjugations on T cell antigen activation
Fig. 2 shows the average IL-2 production by T cells in the
presence of eachCP conjugate relative to a control of 0.5%DMSO.
All but one of the lipid conjugatedCP analogues (LP2) proved to be
more effective than CP (84.86±30.95 vs. 56.95 ±15.69% IL-2
production at 50 μM, mean±SD, respectively). The water-soluble
GS proved capable of inhibiting IL-2 production relative to diluent
controls (82.95±14.96% vs. 100±14.92%, respectively;
P=0.028). This inhibition was significantly less compared to CP
(82.95±14.96% vs. 56.95±15.69%, respectively; P=0.002). The
mono-palmitate conjugate of CP (LP1, 50 μM) resulted in no
quantifiable IL-2 being produced. Thiswas due to its toxic effect on
cells (see section below on proliferation and viability). LP3 demo-
nstrated a 1.5 times increase in inhibition when compared to CP0 at
50 μM, resulting in 39.43±11.58% IL-2 production (P=0.016).
Myristoylation also resulted in a significant improvement on CP's
ability to inhibit IL-2 production (P=2.6×10−4) to 28.85±9.04%
IL-2 production. The most effective improvements on CP's ability
to inhibit IL-2 production were LA (P=3.0×10−7), resulting in
12.08±3.34% IL-2 production when tested at 50 μM. LAwas also
shown to be the most effective inhibitor of IL-2 production at
25μMand 10μM(data not shown). All conjugations including CP
demonstrated dose responsiveness (data not shown).
Fig. 4. The influence of CP conjugates on IL-2 production induced by CD3
cross-linking. Percent IL-2 production by T cells stimulated with CD3 cross-
linking by soluble 2C11. Conjugates were tested at 50 μM and results calculated
with respect to a control of 0.5% DMSO. All conjugates were tested
simultaneously in triplicate wells, and each experiment was performed three
times.
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The effect of CP conjugates on Tcell proliferation was assessed
by [3H]-thymidine uptake (data not shown). The parent compound,
CP, resulted in a proliferation response of 79.93%±10.48 S.D.
relative to controls. Besides LP1, which resulted in a dramatic drop
on cell proliferation to only 1.09%±0.96 S.D. proliferation relative
to control, the only conjugate resulting in a significant reduction in
cell proliferation when compared to CP was LP3 at 60.05%±
10.36 S.D. proliferation relative to DMSO (P=0.008 relative to
CP). Neither, MYR (74.46%±19.24 S.D.) nor LA (88.66%±
5.64 S.D.) resulted in significant changes in cell proliferation
when compared to CP (PN0.05).
Cell proliferation assayswere coupledwith trypan blue staining
to determine the CP conjugate's ability to disrupt the T cell mem-
brane and thereby affect the cell's viability. The only conjugate to
result in a percent viability below 90% relative to the DMSO
control was LP1, which resulted in a viability of 14.72%±9.89 S.
D. CP presented with a viability of 98.39%±1.69 S.D.; LP3 gave
93.64% ±2.85 S.D.;MYR resulted in 95.35%±3.44 S.D.; andLA
demonstrated a viability of 94.97%±2.38 S.D. Taken together, the
proliferation and viability studies demonstrate that LP1 is cyto-
toxic, whereas LP3, MYR, and LA do not inhibit IL-2 production
due to cytotoxicity.
3.3. Effect of CP conjugations on IL-2 production following T
cell stimulation with:
3.3.1. PMA and ionomycin
In an attempt to understand if the mechanism of action of these
compounds was different to that proposed for CP alone, exper-
iments similar to those performed byWang et al. were performed
[28]. To activate the T cell downstream from the TCR, 2B4 cells
were stimulated with PMA and ionomycin. No conjugate demon-
strated any ability to inhibit IL-2 production, in fact, all conju-
gates tested herein resulted in higher amounts of IL-2 production
than the DMSO control, as shown in Fig. 3.
3.3.2. CD3 cross-linking
2B4 cells were next stimulated with CD3 cross-linking anti-
bodies to bypass the TCRα/β antigen recognition subunits. Fig. 4
shows the results of cross-linking with soluble 2C11. The same
experiments were repeated with immobilized, plate-bound 2C11Fig. 3. Percent IL-2 production by T cells following PMA and ionomycin
stimulation in the presence of CP conjugates. Conjugates were tested at 50 μM
and results calculated with respect to a control of 0.5% DMSO.(data not shown). The results are expressed in terms of percent
IL-2 produced compared to a control of 0.5% DMSO. With
soluble, as with plate-bound 2C11, CD3 stimulation in the
presence of CP at 50 μM did not inhibit IL-2 production
(120.06%±19.42 S.D. and 152.31%±24.82 S.D. respectively).
CD3 stimulation in the presence of MYR at 50 μM also did not
inhibit IL-2 production with 122.04%±27.04 S.D. using bound
antibody, and 102.38%±23.26 S.D. using soluble antibody. LP3
and LA were the only conjugates to demonstrate an ability to
inhibit IL-2 production. When treated with LA, IL-2 production
after CD3 cross-linking was decreased to 66.83%±25.11 S.D.
(P=1.71×10−3) with immobilized 2C11, and 78.30%±17.13 S.
D. (P=0.012) with soluble 2C11 at 50 μM. LP3 at 50 μM was
able to inhibit IL-2 production to 76.09%±24.81 S.D. (P=0.014)
when immobilized antibody was used but was unable to inhibit
IL-2 production when soluble antibody was used as a stimulant
(111.94%±20.38 S.D.).
3.3.3. Staphylococcal enterotoxin A (SEA) activation
This method activates T cells by cross-linking the MHC
molecule of the antigen-presenting cell (LK 35.2) to the T cell's
TCR-β (Vβ) chain, thereby inducing T cell activation [38,39].
The results of these experiments are shown in Fig. 5. In this
model, MYRwas not able to inhibit IL-2 production, resulting inFig. 5. The influence of CP conjugates on IL-2 production induced by the
superantigen SEA. Percent IL-2 production by T cells stimulated with SEA.
Conjugates were tested at 50 μM and results calculated with respect to a control
of 0.5% DMSO. All conjugates were tested simultaneously in triplicate wells,
and each experiment was performed three times.
Fig. 7. Binding of CP and conjugations to model membranes. Each conjugate was
tested at 50 μM (0.5% DMSO) on membranes composed of DMPC: DMPG at
70:30. LP1:–••–, LP2:––••, LP3:•••,MYR: , LA:–•–, CP:—, and
GS: – –.
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production marginally at 81.30%±26.10 S.D., statistical signi-
ficance was not reached (P=0.07). CP was able to inhibit IL-2
production to 54.76%±8.87 S.D. (P=1.48×10−7), and LAwas
able to bring IL-2 production to 37.04%±3.84 S.D. (P=1.0×10−10)
relative to the controls.
3.3.4. TCR cross-linking
Tcells were activated by cross-linking the TCRβ through its Cβ
FG loop [40] using the H57-597 antibody in either soluble or
immobilized forms. Fig. 6 shows the results obtained using soluble
antibodywith data expressed in terms of%IL-2 produced compared
to the DMSO control. In both soluble and bound antibody acti-
vation models, only LAwas able to inhibit IL-2 production signi-
ficantly, producing 74.54%±23.20 S.D. (P=0.01) when the
antibody is plate bound, and 75.95% ±11.66 S.D. (P=0.00038)
when the antibody is administered soluble. Although MYR was
able to inhibit IL-2 production when the cells were activated using
bound antibody to 91.40%±20.07 S.D., statistical significance
was not reached (P=0.3). Similarly, as shown in Fig. 6, there was
no statistically significant inhibition with MYR using soluble
antibody. All other peptides tested resulted in %IL-2 production
levels equal to or greater than that observed by the DMSO control.
3.4. Effect of CP conjugations on model membrane binding
To correlate function with the effect of conjugation on CP's
ability to bind to model lipid membranes, 50 μM of each con-
jugate was passed over membranes composed of DMPC and
DMPG in a 70:30 ratio and analysed by biosensor technology
(Fig. 7). All conjugates were added to membranes at time 0 and
were dissociated at 1200 s. In this study, CP presented with a
response unit (RU) value of 5200 RU at the end of the association
phase, declining to 1700 RU after dissociation. Interestingly, LA,
which was the most active conjugate in vitro, showed a slow but
strong binding curve with no decrease in RU during the dis-
sociation phase. The final RU observed for LA was 2900 RU,
which could not be removed, implying it was firmly bound to the
lipid layer. MYR showed similar results with a slow association
phase (compared to CP), and an inability to be removed from theFig. 6. The influence of CP conjugates on IL-2 production induced by soluble
antibody TCR-β cross-linking. Percent IL-2 production by T cells stimulated
with TCRβ cross-linking with soluble H57-597 antibody. Conjugates were
tested at 50 μM and results calculated with respect to a control of 0.5% DMSO.
All conjugates were tested simultaneously in triplicate wells, and each
experiment was performed three times.membrane surface. MYR's final RU value was approximately
4000 RU. The carbohydrate conjugate GS showed an adsorption
of about 1000 RU but rapidly dropped to approximately 300 RU
as soon as the dissociation phase began. Of the Tris conjugates
(reprinted with permission from Ali et al., copyright 2005, Ame-
rican Chemical Society [41]), the strongest binding was observed
with LP1. LP1's association levelled at roughly 18400 RU, and
upon dissociation, dropped to 17500 RU, which was about ten
times more than that observed for CP (1700 RU). LP2 resulted in
6000 RU bound after the dissociation phase, and LP3 resulted in
the least binding at roughly 3500RU remaining after dissociation.
In all cases, lipopeptides could not be removed from the bound
lipid, suggesting that at least part of the reason for their increased
effectiveness in vitro is likely due to an improved ability to remain
bound to lipid membranes when compared to CP [41].
3.5. Therapeutic effect of peptide conjugations on a rat model
of adjuvant-induced arthritis
To determine whether or not the in vitro activities of these
peptide conjugations carried over to in vivo systems, rats with
adjuvant-induced arthritis were given subcutaneous injections of
each conjugate (excluding LP1 and LP2) to determine the effect-
iveness of each conjugate. Six different criteria were utilized to
determine the severity of arthritis. These included digital caliper
measurements of paw thickness, paw width, and ankle width, rat
weight and the number of arthritic joints were assessed daily.
Measurements were normalized by setting the measurement from
the day before arthritis was observed to 100% and calculating all
subsequent measurements based on this value. A statistical
analysis comparing the slopes (progression) obtained by plotting
condition (such as ankle thickness or paw width) on the y-axis vs.
day on the x-axis, of each of the six criteria showed that all con-
jugations reduced the progression of arthritis significantly
(Pb0.05) in at least one of the six criteria with the exception of
MYR, which approached significance in the ankle thickness
criteria (P=0.055). Fig. 8 shows the overall severity of arthritis in
Fig. 9. A potential mode of action of CP. (a) The normal transmembrane charge
interactions between the TCR α/β and the CD3εδ, CD3ζζ, and the CD3γε
chains essential in the formation of a functional T cell receptor. (b) Proposed
transmembrane interactions between CP's arginine and lysine residues and those
of the CD3δε and CD3ζζ chains. This model predicts that CP disrupts the
transmembrane charges between the TCRα and the CD3δε and CD3ζζ chains.
This results in a non-functioning T cell receptor consisting of only the TCRα,
TCRβ, and the CD3γε subunits.
Fig. 8. The influence of CP conjugates as a treatment in the rat adjuvant-induced
arthritis model. Rats were treated subcutaneously with 6 mg of peptide for 4
consecutive days starting one day after arthritis was diagnosed. Results are
presented as the overall paw swelling averaged for all measurements over time
(days). 100% is set at Day 0 (the day arthritis was diagnosed). CP:—; Squalane:
– – • •; LP3: – – •; LA: – • –; MYR: • • •; Cyclosporin (Cyc): – • • –;
GS: – –.
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from every rat in each treatment group and plotting this over time
(day). In agreement with results presented by Kurosaka et al.
(manuscript submitted), LP3 administered subcutaneously show-
ed no improvement on CP's ability to inhibit arthritis in this
model. By contrast, MYR and LA both improved CP's ability to
treat arthritis. Rats treated with GS showed a response similar to
that observed for cyclosporin.
4. Discussion
In this study, the effectiveness of various conjugations on an
insoluble hydrophobic peptide (CP) was examined. Changes in
CP's ability to inhibit T cell activation was observed following
each conjugation. Efficacy of lipid conjugation was dependent
upon the type and number of lipid groups attached to CP. In the
case of myristoylation, CP's ability to inhibit antigen activation
was significantly increased in vitro. Myristoylation is a well-
known post-translational modification used by cells to anchor
proteins to the plasma membrane and includes examples such as
myristoylated alanine-rich C kinase substrate and endothelial
nitric oxide synthase [42]. The same can be said of palmitoylated
CP conjugates, since many proteins are stably anchored to the cell
membrane upon palmitoylation [43]. Although the Tris-lipidation
employed here is different from the N-palmitoylation normally
used by the cell, the structural similarity of the Tris molecule to
glycerol allows it to mimic naturally occurring glycerides. In the
Tris molecule, however, the central carbon atom is symmetrical
and lends itself to derivatisation by avoiding structural isomer-
ization, which can be a difficulty in the synthesis and purification
of glycerol derivatives. Tris-lipidation has previously been proven
successful in the delivery of methotrexate in animal models
demonstrating reduced toxicity and improved bioavailability [44].
The results of the antigen presentation assay, proliferation assay,
and viability studies for the Tris-conjugates have recently been
published elsewhere [41], where it was argued that the differential
results between each of the compounds was due to differential
localization within the cell, or their variable susceptibility to
enzyme digestion as has been reported by other groups [24,45].Recent studies have shown that lipid conjugation can increase
the functional activity of peptides [46–48]. In agreement with
these studies, lipoamino acid conjugation of CP enhanced CP
function. As noted by Toth et al., it is possible to lipoconjugate a
compound using lipoamino acids at the N-terminal while reta-
ining the parent compound's biological activity [49]. While the
lipoamino acid conjugate was the most active compound tested
herein, the carbohydrate conjugated CP was surprisingly one of
the least active. When CP was conjugated to glucosesuccinate,
this compound failed to inhibit T cell activation in the antigen
presentation assay. Intuitively, it was thought that an increase in
CP's solubility by glycosylation would increase its bioavailability
and hence its activity. However, the results were contrary to
expectations and suggested that the requirements for an effective
drug delivery agent must take into account the site of action of the
drug. If a drug ismore effective in a hydrophilic environment such
as the cytosol, then a more soluble carrier may be useful. Whereas
if the drug is to act in a hydrophobic region such as a trans-
membrane domain, this aspect should be reflected in the carrier. In
this instance, the hydrophilic nature of the glucosesuccinate may
have sequestered the short hydrophobic CP from successfully
reaching its target or at least inhibited CP from binding to the
cell's membrane. In this respect, localization experiments with
FITC-labelled peptides using confocal microscopy may be useful
and is currently under investigation. Using surface plasmon reso-
nance experiments GS showed no quantifiable binding to model
membrane bilayers (Fig. 7), supporting the above argument.
Conjugates were next tested for their ability to retain the parent
compounds original site of biological activity. Similar to previous
experiments with CP [28], the lack of activity from the conjugates
in the PMA/ionomycin activation and CD3ε cross-linking expe-
riments suggested that these conjugations were active upstream of
the CD3 complex, likely at the TCR α/β interface. To further test
this, T cells were activated by either the superantigen SEA, which
Table 1
Summary of CP activity in different activation models
Activation IL-2 production
TCRαβ dependent Antigen −
SEA −
TCR-β cross-linking +
CD3 dependent CD3 cross-linking +
non TCR-CD3 dependent PMA/ionmycin +
Results of CP activity in each of the activation models tested were the following:
“−” represents an inhibition of IL-2 production to levels significantly below that
presented by the DMSO controls (Pb0.05); and “+” representing IL-2
production equal to or greater than levels presented by DMSO controls.
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gen-presenting cell resulting in a similar signalling cascade as
observed with peptide antigens [38,50,51] or by the TCR-β-
specific H57-597 antibody [34,40]. Core peptide and LA were
able to significantly inhibit IL-2 production during SEA
activation (Pb0.05), LP3 showed partial inhibition (P=0.07),
whereasMYR showed no inhibition, suggesting slightly different
modes of action when compared to CP for LP3 and MYR.
Activation through the TCRβ chain by either soluble or plate-
bound H57-597 showed that only LAwas capable of significantly
inhibiting IL-2 production, albeit only to approximately 75% of
control, suggesting that these compounds associate more closely
with the TCRα chain than the TCRβ chain as utilized in this
model of activation in agreement with the hypothesized mode of
CP action (Fig. 9).
Sigalov recently proposed a model of T cell activation in
which, depending upon the strength of the TCR–peptide–MHC
interaction, the CD3ζζ, CD3δε and CD3γε signalling oligo-
mers dissociate differentially from the TCRαβ subunit [52].
These signalling dimers then interact with other TCRs to result in
higher order signalling complexes and an amplification of the
activation signal.Within this context, it has been proposed that CP
inhibits TCRα interactions with its associated CD3 chains,
creating a state where the CD3δε and CD3ζζ dimers are “pre-
dissociated” from the TCRαβ antigen recognition subunit [52].
Upon antigen activation, which requires a fully assembled TCR-
CD3molecule, the CD3δε and ζζ subunits are already dissociated
from the TCRα resulting in no activation. To highlight the agre-
ement between the experimental results and this model, Table 1
summarizes CP's ability to inhibit IL-2 production following each
of the stimulation methods examined. Neither PMA/ionomycin
activation or CD3 cross-linking require the CD3 chains to be
associated with the TCRαβ, which may explain why CP has no
effect. By contrast, CP successfully inhibits IL-2 production
requiring complete CD3 association with the TCRαβ subunit
(antigen and SEA activation). However, CP is not capable of
inhibiting IL-2 production when activation is through cross-
linking with a monoclonal antibody directed against the TCRβ
chains. This may be because CP does not affect the interactions
between the TCRβ and the CD3γε, which has been shown to
involve extracellular [34,40,53] as well as transmembrane charge
interactions [26], making this interaction possibly harder to
disrupt. These results taken together, suggest that CP activity may
be centred around the interactions between the TCRα and its
associated CD3δε and ζζ subunits (Fig. 9).The proposed first step in attempting to destabilize the TCR by
CP is membrane binding, followed by membrane insertion. To
determine the effect of conjugation on the ability of each peptide
to bind to artificial membranes, each conjugate was examined
using surface plasmon resonance. When tested with artificial
membrane bilayers composed of 70:30 DMPC:DMPG (Fig. 9),
each lipid conjugate was found to bind irreversibly. Extensive
washing was incapable of removing bound peptide. With the
exception of LP2, the irreversible binding observed for the lipid
conjugations may be the reason for their increased ability to
inhibit IL-2 production in the antigen presentation assay. The high
binding of LP1, and its ability to enter membranes much more
rapidly than its di- and tri-lipidated counterparts [54], is poten-
tially the reason for its cytotoxicity as observed previously [41].
Surprisingly, GS was not capable of binding to artificial mem-
branes in this system.
To evaluate the clinical efficacy of these conjugates rats with
adjuvant-induced arthritis were treated with GS, LA, MYR, LP3,
CP, and cyclosporin, for 4 consecutive days. Cyclosporin had a
good effect on arthritis outcome. As expected, animals treated
withCP, LA, andMYRalso had a good outcome andmirrored the
results obtained from the antigen presentation assay. Not expected
was the ability of GS to abolish arthritis, such that only a few
joints remained red, with minimal swelling. This discordance
raises an important point of this study in that loss of activity in
vitro by conjugation (or at least partial loss) does not correlate
with loss of activity in vivo. It is possible that GS, being water-
soluble, enters the bloodstream with greater ease where serum
proteases, or other enzymes, cleave the glucosesuccinate moiety
resulting in an active form of CP. Further work is required to
determine the precise mechanism of action of GS. Although few
animals were employed in these experiments, statistically signi-
ficant results were observed with CP conjugation.
In summary, conjugation of CP with lipids/sugars enhances
activity without altering the site of action of peptide function.
Further assessment of these compounds as potential therapeutic
agents is currently the focus of ongoing research within our
laboratory.
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